A probiotic lozenge with Lactobacillus brevis CD2 that helps prevent and reduce oral mucositis in patients undergoing radiotherapy, chemotherapy, or Hematopoietic Stem Cell Transplantation (HSCT).
Cancer therapies like chemotherapy, radiotherapy, and stem cell transplants are vital for treatment, but they often cause severe side effects. One of the most painful conditions patients experience is oral mucositis—severe mouth ulcers and tissue inflammation that make eating, swallowing, and speaking extremely difficult. Beyond the physical discomfort, these painful lesions frequently force doctors to delay or interrupt crucial cancer treatments.
At Nexgen Pharma, we are dedicated to providing Oncology Supportive Care based solutions designed to help patients manage treatment-induced complications and maintain their therapy schedules with greater comfort.
A probiotic lozenge with Lactobacillus brevis CD2 that helps prevent and reduce oral mucositis in patients undergoing radiotherapy, chemotherapy, or Hematopoietic Stem Cell Transplantation (HSCT).
Rather than simply masking pain, Nexgen Pharma focuses on therapies that actively soothe and protect the oral mucosa. Utilizing specialized, clinically backed probiotic strains with powerful anti-inflammatory properties, these formulations help lower nitric oxide levels, calm tissue swelling, and preserve the oral lining during aggressive cancer treatments.
Delivered as smooth oral probiotic lozenges, these beneficial bacteria provide direct, localized action on sensitive mouth tissues. Utilizing probiotic lozenges offers a practical, gentle solution for individuals struggling with swallowing difficulties or dry mouth.
Targeted Mucositis Care: Recognized among the best probiotics for chemo-radiotherapy mucosisits, helping reduce the risk of severe ulcers before treatment starts and aiding the healing of existing lesions.
Pain & Inflammation Relief: Significantly eases oral soreness, allowing patients to swallow and maintain proper nutrition.
Uninterrupted Therapy: Helps prevent treatment delays, allowing oncology teams to keep chemotherapy and radiation schedules on track.
Enhanced Comfort in Advanced Care: Serves as effective probiotics for pallative care in cancer, boosting daily Quality of Life (QoL) and overall well-being.
Nexgen Pharma remains committed to advancing supportive cancer care—helping patients manage side effects, regain comfort, and focus on their path to recovery.
The key difference between Mucofan and Orabiome is their intended use. Orabiome is formulated for everyday oral care, whereas Mucofan is intended for patients undergoing cancer therapy. Mucofan contains a higher count of the Lactobacillus brevis CD2 strain (CFU) per lozenge/tablet and is intended to support oral health during cancer treatment. Its use should always be guided by the patient’s oncology team.
Maintaining good oral hygiene is particularly important during chemotherapy and radiotherapy. Patients are generally advised to use a soft-bristled toothbrush and alcohol-free mouth rinses, avoid spicy, acidic, and very hot foods, and keep the mouth moist by drinking water frequently. Always follow the personalised oral care recommendations provided by your oncology team.
Cancer patients should promptly report new mouth sores, pain while swallowing, white patches, bleeding, persistent oral discomfort, or difficulty eating and drinking. Early reporting helps the healthcare team assess oral complications, including oral mucositis, and recommend appropriate management.
Before using Mucofan alongside prescribed mouth rinses, medications, or other oral care products, patients should consult their oncology team. The healthcare professional can evaluate potential interactions and determine whether the product is appropriate during the patient’s cancer treatment.
Caregivers can support oral health by checking the patient’s mouth daily, encouraging adequate fluid intake, offering soft and easy-to-swallow foods, and maintaining gentle oral hygiene. Any new sores, bleeding, pain, or difficulty eating and drinking should be promptly reported to the healthcare team.
Hospitals, oncologists, and oncology centres can contact NextGen Pharma for product availability, scientific information, and professional product-related enquiries regarding Mucofan. For further details, please email bizsupport@nextgenpharmaindia.com.
Probiotics containing scientifically studied strains are being explored for their potential role in supporting oral health during chemotherapy and radiotherapy. When considering the best probiotics for chemo-radiotherapy-induced oral mucositis, it is important to evaluate strain-specific clinical evidence, dosage, formulation, and patient suitability. Mucofan contains the Lactobacillus brevis CD2 strain and is intended for patients undergoing cancer therapy. Patients should consult their oncologist before using any probiotic during cancer treatment.
The role of probiotics in palliative care in cancer patients is an area of clinical interest, particularly in relation to oral and digestive health. Certain probiotic strains are being studied for their potential supportive role in maintaining microbial balance and oral wellbeing. However, their suitability depends on the patient’s condition, immune status, and treatment plan. Any probiotic use during palliative cancer care should be discussed with the treating oncologist or palliative care specialist.